Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
Saved in:
| Title: | Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. |
|---|---|
| Authors: | Sperling AS; Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA.; Division of Hematology, Stanford University, Palo Alto, CA 94305, USA., Derman BA; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA., Nikiforow S; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Alonso A; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ikegawa S; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Orwitz N; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA., Quinn DS; Novartis BioMedical Research, Cambridge, MA 02139, USA., Pearson D; Novartis BioMedical Research, Basel 4056, Switzerland., Bu D; Novartis BioMedical Research, Cambridge, MA 02139, USA., Milanez-Almeida P; Novartis BioMedical Research, Cambridge, MA 02139, USA., Mataraza J; Novartis BioMedical Research, Cambridge, MA 02139, USA., Nadeem O; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Liegel J; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., D'Souza A; Medical College of Wisconsin, Milwaukee, WI 53226, USA., Charles A; Novartis BioMedical Research, Cambridge, MA 02139, USA., Credi M; Novartis BioMedical Research, Cambridge, MA 02139, USA., Ritz J; Dana-Farber Cancer Institute, Boston, MA 02215, USA., Jakubowiak AJ; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL 60637, USA., De Vita S; Novartis BioMedical Research, Cambridge, MA 02139, USA., Munshi NC; Dana-Farber Cancer Institute, Boston, MA 02215, USA. |
| Source: | Science translational medicine [Sci Transl Med] 2026 May 27; Vol. 18 (851), pp. eadx1799. Date of Electronic Publication: 2026 May 27. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1946-6242 |
|---|---|
| DOI: | 10.1126/scitranslmed.adx1799 |
